A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms SELENE
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 9 Oct 2021 to 3 Aug 2021.
    • 29 Jun 2017 Planned primary completion date changed from 9 Oct 2017 to 15 Nov 2018.
    • 24 Feb 2017 Planned End Date changed from 1 Aug 2021 to 1 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top